CRYSTALLINE ANHYDROUS FORM OF CABAZITAXEL, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF Russian patent published in 2018 - IPC C07D305/14 A61K31/337 A61P35/00 

FIELD: chemistry.

SUBSTANCE: present invention relates to a novel anhydrous crystalline form, called Form H, Cabazitaxel of Formula (I) . Anhydrous crystalline form has one or more of the following: X-ray diffraction pattern X-RPD, obtained using lengths λ₁ and λ₂ waves of the copper spectrum equal to 1.54056 Å and 1.54439 Å, respectively, containing distinctive reflections, expressed as the values of the scattering angle of 2-theta degrees at 5.8, 6.5, 8.1, 9.5, 10.9, 11.5, 12.2, 13.0, 14.1, 14.8, 16.8, 17.2, 19.0, 19.4, 20.1, 21.9 and 24.0 ± 0.2; X-ray diffraction pattern X-RPD, obtained using lengths λ₁ and λ₂ copper spectrum waves of 1.54056 Å and 1.54439 Å, respectively, substantially as shown in Fig. 1; TG and DTA profiles obtained with a linear thermal power of 10 °C / min, essentially as shown in Fig. 3; The DSC profile obtained with a linear thermal power of 10 °C / min, essentially as shown in Fig. 4. Pharmaceutical composition for the treatment of cancer and a method for the preparation of an anhydrous crystalline form of H.

EFFECT: new form of H Cabazitaxel has a reduced ability to absorb moisture and a high degree of purity.

4 cl, 4 dwg, 3 ex